Brief: Athira Pharma Advances Phase 2/3 Lift-Ad Clinical Study Of Fosgonimeton In Mild-To-Moderate Alzheimer’S Patients Following Independent, Unblinded Interim Analysis

LeonaBio

17/10/2022 12:14

Oct 17 (Reuters) - Athira Pharma Inc  ATHA.O :
    * ATHIRA PHARMA ADVANCES PHASE 2/3 LIFT-AD CLINICAL STUDY OF
FOSGONIMETON IN MILD-TO-MODERATE ALZHEIMER’S PATIENTS FOLLOWING
INDEPENDENT, UNBLINDED INTERIM ANALYSIS
    * ATHIRA PHARMA INC - RESULTS SUPPORT POTENTIAL CLINICALLY
MEANINGFUL ACTIVITY OF FOSGONIMETON WITHOUT BACKGROUND THERAPY
AND MITIGATE PROGRAM RISK
    * ATHIRA PHARMA INC - TARGETS COMPLETION OF ENROLLMENT IN
MID-2023
AND TOPLINE RESULTS IN EARLY 2024
    * ATHIRA PHARMA - INDEPENDENT DATA MONITORING COMMITTEE
RECOMMENDED CONTINUATION OF LIFT-AD STUDY OF FOSGONIMETON IN
PATIENTS WITH MILD-TO-MODERATE ALZHEIMER'S DISEASE

Source text for Eikon:  ID:nGNX8fKbx3 
Further company coverage:  ATHA.O 
 ((Reuters.Briefs@thomsonreuters.com;;))